Day: May 8, 2024

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Read More


DURHAM, N.C. --(BUSINESS WIRE)--May 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination,